Long-Term Implantability of Resorbable Carboxymethyl Cellulose/Chitosan Microspheres in a Rabbit Renal Arterial Embolization Model
To determine the physiologic response to resorbable carboxymethyl cellulose/chitosan (CMC/CN) microspheres in a long-term rabbit model, including the clinical response, gross pathology, and histopathology.
Materials and Methods
Six rabbits were embolized with CMC/CN microspheres (300–500 µm) in one kidney via an inferior renal artery branch. Angiography was performed immediately before and after embolization and prior to killing at 6 months (180 ± 7 days, n = 3) and 12 months (365 ± 10 days, n = 3). A complete necropsy was performed on each animal with dissection of the kidneys and harvesting of additional tissues as per ISO-10993-part 6 and ISO-10993-part 11 guidelines. All tissues were processed and stained for pathological analysis.
The caudal third of target kidneys was successfully embolized with CMC/CN microspheres. Over the course of the study, there were neither notable clinical signs in either embolization group nor significant changes in the tissue/body weight ratio between 6- and 12-month time points. Gross examination revealed that all embolized kidneys had morphologic features consistent with infarction resulted from microsphere delivery. The percentage of infarction decreased from 9.1% ± 5.7% at 6 months to 1.9% ± 0.4% at 12 months. Microscopically, infarcted areas demonstrated evidence of chronic injury and repair, including loss of renal parenchyma with replacement fibrosis, tubular regeneration, and minimal to mild lymphoplasmacytic inflammation without any active changes such as necrosis or neutrophilic inflammation.
No systemic toxicity was observed in the animals 6 and 12 months after CMC/CN microspheres delivery. The local tissue response was mild.
KeywordsImplantability Bioresorbable microspheres Arterial embolization Local effect Systemic toxicity
This study was partially supported by a research Grant (Weng 2015, 00049685) sponsored by EmboMedics Inc.
Compliance with Ethical Standards
Conflict of interest
Lihui Weng received research grants from EmboMedics and also is a shareholder of EmboMedics Inc. Omid Souresrafil is shareholder of EmboMedics Inc. Davis Seelig has no conflict of interest.
- 19.Kumar V, Abbas K, Fausto N, et al. Acute and chronic inflammation. In: Kumar V, Abbas K, Fausto N, et al., editors. Robbins and Cotran pathologic basis of disease. Philadelphia, PA: Saunders; 2010. p. 43–78.Google Scholar
- 22.Shamekhi MA, Rabiee A, Mirzadeh H, Mahdavi H, Mohebbi-Kalhori D, Baghaban Eslaminejad M. Fabrication and characterization of hydrothermal cross-linked chitosan porous scaffolds for cartilage tissue engineering applications. Mater Sci Eng C Mater Biol Appl. 2017;80:532–42.CrossRefPubMedGoogle Scholar
- 23.ISO 10993-6:2009. Biological evaluation of medical devices-part 6: tests for local effects after implantation. Geneva: International Organization for Standardization; 2009.Google Scholar
- 24.ISO 10993-11:2009. Biological evaluation of medical devices—part 11: tests for systemic toxicity. Geneva: International Organization for Standardization; 2009.Google Scholar